OTC Products in Chewgels Technology

During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.  

Offering end-to-end solutions in Softgel technologies from development across delivery. Learn more about who we are.

Procaps, developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents, has partnered with CPHI Barcelona to support sustainability initiatives, to be highlighted at the CPHI Worldwide event in Barcelona in October 2023. 

Simplifying treatments. Increasing Patient Compliance. Innovating in Sustainable Products.

In our packed out content sessions at CPHI Barcelona this year we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field.   

Get to know more about our expanded capabilities for proximity and to better serve our customers and prospect partners in their markets.

Sofgen Pharmaceuticals is supporting the war on waste through Unigel®, a unique smart softgel that allows multiple APIs to be included in a single dose.

UnigelTM is aimed for brands who want their patients to have simplicity and effectiveness without comprising quality, backed by science and technology.

This revolutionary form provides different configurations for Rx, OTC and specialized nutraceutical products.

UnigelTM understands consumers requirements, but also provides customers with the quality, regulatory expertise, time and cost effectiveness they deserve.

Learn how to meet the demands of a modern industry with an integrated CDMO for tailor-made advanced Softgel technologies, and discover what our expansion into North America will mean for our production capacities and growth in our latest infographic.

Our success developing precise analythical methods and deliver unmatched quality in routine analytics gives us experience that is vital to the success of your projects. 

The Pharma industry is expected to reach $1.9Tn in revenue by 2027, increasing at a rate of 3-6% per year, according to IQVIA1, with some regions being driven by volume, and others by innovation. Growth in developed economies is projected to be slow, while other regions such as Latin America, Eastern Europe and parts of Asia are expected to have a strong growth. As the pharmaceutical industry continues to evolve, CDMOs will play an increasingly important role in drug development and manufacturing. 

Unigel™️,  is a first-to-market technology designed to combine multiple API formulations in one single soft gelatin capsule, offering multi-phase therapies, improving bioavailability, reducing manufacturing costs, and achieving superior adherence to different therapies. Unigel™️ technology provides various forms for fixed-dose combinations, such as a softgel in a softgel, a tablet in a softgel, granules in a softgel, or any combination to address challenges of multiactive formulation, offering unique prescription, otc and otx products.

Top 5 Global Producer of Pharmaceutical Softgels to Expand Production Capacity in the United States by 1.8 Billion Capsules Annually

USFDA Approved 86,000 Square Foot Facility Located in West Palm Beach, Florida to Accelerate Time-To-Market Response & Lower Cost of Distribution to the North American Market

Meet our vegetarian softgel technology, Versagel™️, a versatile option for the encapsulation of high viscous, semisolid or high pH fill contents. This is a platform that has been built at Procaps from different standpoints such as: Formulation, R&D, Process, Product and Experience.

Strong Financial Performance Enables Procaps Group to Launch Private Placement of Senior Notes to Refinance Existing Debt with New Institutional Investors Utilizing a Lower Cost of Capital & Expanded Duration to Accelerate Growth Strategy

The Softgel Capsule is a superior delivery system with wide-ranging applications. They are a solid dosage form composed of two gelatin films that contain semisolid or liquid APIs protected by an external, hermetically sealed cover. They ensure high precision dosage by achieving homogeneity of ingredients.

Explore the series of Learning Labs at CPHI North America across several product innovation categories in which thought leaders at our exhibitors showcase their extensive expertise in all areas of the pharma supply chain, offering industry insights across drug manufacturing, outsourcing, pharma ingredients, drug delivery and packaging.

A key factor in our market success is having a R&D team working continuously on the development of formulas and pharmaceutical technologies. Our experience is at your disposal. Contact us and get to know us more! 

As consumers become increasingly knowledgeable about the different delivery formats available, so they continue to demand more from both pharmaceutical and nutraceutical products. As a result, the race to create the next ‘super pill’ has intensified. One of the leading contenders in this race is Unigel softgel.

Selecting the right delivery format for your next product launch is not an easy decision, essentially it should depend on several factors such as dosage, formulation, absorption, quality, but have you thought about consumer preference and experience when choosing the format for your next big launch? Which formats are today providing enjoyable and consumer experiences, being tasteful, convenient, and delivering the required nutrition consumers are looking for?

With advances in technology transforming drug delivery systems, these are exciting times for the pharmaceutical industry. Not only are companies finding innovative ways to optimise manufacturing processes, but more importantly, new technologies are being developed that improve the lives of patients.

Procaps counts with Deep knowledge and extensive experience in the Development and manufacturing of complex hormone therapy drugs, supported by our advanced softgel technologies. Learn more

Highly stable and offering a long shelf life, soft gelatin (softgel) capsules have gained popularity as an alternative supplement delivery system to oils and pills. They can also help manufacturers enhance the bioavailability of active pharmaceutical ingredients (APIs).

This article is aimed to offer a general review of the fixed dose combinations (FDC), the manufacturing technologies and their applications, benefits and setbacks as well as a case study to illustrate the product concept based on the new technological platform of Unigel®️ for FDCs in soft gelatin capsules

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner. 

The Company Showcase profiles offer a library of free to access, downloadable content, including videos and webinars, reports, whitepapers and product brochures, from the Pharma suppliers and service providers you’d look to meet at our events.

One of the most frequent issues in product development of soft gelatin capsules is dissolution performance. Gelatin is a protein containing terminal reactive amino o carboxylic groups which proceed to crosslinking reactions, leading to the formation of insoluble high molecular weight chains that decrease or limit the release of the fill content of the capsules to the dissolution media. The progress of this reaction will depend on the content of high molecular weight chains, the content of free groups to react in gelatin or the reactive impurities in excipients. In product formulation, some properties of the gelatin such as the gelatin type and the molecular weight have been identified to determine the dissolution of the product. In regards to the gelatin formulation, some relevant variables are the type and content of plasticizer.

Appearing in the September 2020 edition of Tablets & Capsules, this article summarizes a method for rapid and accurate determination of API concentration in the fill of soft gelatin capsules while little or no sample preparation. Applying chemometric models to near-infrared spectrum data allows scientists to predict the API content in samples from the manufacturing process and the final product.

The present is an overview of the state-of-the-art for vegetarian soft capsules in terms of materials (sourcing and demand), applications, processing, products and a general insight of the current state of materials and technology of these gelatin alternatives.

The present is an overview of the state-of-the-art for vegetarian soft capsules in terms of materials (sourcing and demand), applications, processing, products and a general insight of the current state of materials and technology of these gelatin alternatives.

Selecting the appropriate dosage form in the development and manufacturing of Cannabis-based products plays an important role in the success of the drug product because the dosage form selected should be able to protect the drug substance during all the shell life and facilitate its handling and administration to patients and consumers.

Learn more on our unigel technology, platform for multi-purpose, multi-dose therapies in fixed dose combinations in softgels. Ready-to-market formulas available. 

Fixed-dose combinations are the preferred approach to simplify the management of chronic diseases such as HIV, asthma, diabetes, lipid regulation, and hypertension by reducing the number of dosage intake and improving efficacy as well as offering a more cost-effective therapeutic option to monotherapy. However, there are various challenges in the fabrication of multi-layered tablets that need to be considered to achieve optimal manufacturing at an industrial scale. This whitepaper from Procaps provides an overview of recent academic works regarding the implementation of how Additive Manufacturing (3D Printing) technologies have emerged to develop pharmaceutical products, particularly the design and manufacturing of dose combination products for chronic patients.

Discover how our passion for innovation turns into revolutionary technologies that are ideal for consumers health and nutrition. Unigel™ is the only technology available for fixed dose combinations, that allows multiple ingredients to co-exist in one single dose

Procaps is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in Latin America and, as of December 31, 2020, had more than 4,700 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions. 

More than 4 decades developing medical solutions for the world.

As an integrated CDMO in Softgel Technologies, we offer end-to-end solutions from development across delivery.We value ourselves as a business partner that can be flexible enough to work with your needs and deliver innovative and specialty products that fit your patients and market needs. Meet with us

This webinar originally aired as part of CPHI Discover - 17-28 May 2021 Latin America is a diverse market with a huge population that has commanded the attention of pharma companies as one to watch. This session will explore how the potential of this dynamic market can be tapped into. Overview of the current market opportunities & challenges across key markets - Brazil, Mexico, Chile, Colombia, Argentina and Central America. Key therapy areas & most promising markets Innovation landscape Potential drivers to the increasing internationalization of the LatAm Pharma Market What has been the impact of the pandemic on the Latam pharmaceutical market?

This webinar originally aired as part of CPHI Discover - 17-28 May 2021 While plant-based diets continue to grow in popularity, the desire to live and act more sustainably and healthfully is on the rise. With our Vegetarian Softgel Technology, Versagel™, companies can now offer their patients and consumers Non-GMO, plant-based softgel products as an optimal solution for their latest demands without losing the versatility and benefits of regular softgel capsules. Changing to a plant-based alternative should not affect overall product performance and quality. Versagel™ offers not only great appearance, but an overall competitive edge, the cornerstone for your next big project. Join us!

The Pharma industry is shifting from volume to value – addressing smaller patient populations and rare diseases. 3D printing (3DP) technologies have a transformational role to play. However, 3DP comprises an array of different additive manufacturing technologies of which only some can be adapted to the use in pharmaceutics. This session will discuss the use of 3D printing in a hospital setting to prepare personalised therapies for paediatric patients. For the first time, 3D printing offers a feasible, rapid and automated approach to prepare oral tailored-dose therapies for patient improving safety and adherence to the treatment. Podcast aired as part of the CPHI Festival of Pharma

New initiatives to boost throughput, efficiency, and customised manufacturing solutions

Funtrition’s new gummy facility in Florida amplifies reach, doubling capacity and reinforcing commitment to global nutraceutical excellence.

Innovations in gummy delivery technology allow brands to cater to consumer demand for efficacious, great-tasting supplement products.

The global demand for ​gummy supplements has witnessed an unprecedented surge in recent years, driven by factors such as convenience, indulgence, and efficacy.

A breakthrough in oral drug delivery technology is helping the pharmaceutical industry to cut plastic waste

Join Frances Zipp, where she will delve into the latest innovations and developments in drug manufacturing and how the industry can embrace 4.0

The pharmaceutical industry faces significant challenges in bringing new drugs to market due to the complexities of the R&D process. These challenges include high costs, lengthy development timelines, and a low success rate. In response to these challenges, a new approach to R&D has emerged: R&D 4.0.
R&D 4.0 leverages advanced technologies such as Deep Learning, Machine Learning, Artificial Intelligence, 3D Printing; among others, to streamline the drug development process and reduce time-to-market. In this webinar, join Procaps Group to explore the role of these technologies to improve the pharmaceutical development process. We will showcase real-world case studies performed, including the utilization of three-dimensional printing technology in the development of complex and customized drug delivery systems. Additionally, we will discuss how Deep Learning algorithms can estimate moisture levels in gelatin mass at different stages of the manufacturing process using spectral data. This approach provides real-time data to optimize the production process and ensure consistent quality. Furthermore, we will explain how Machine Learning algorithms, specifically the Pearson correlation coefficient, are being used to analyse the interaction of different excipients in drug formulations. This analysis helps in optimizing drug formulations to improve stability and efficacy. Explore with Procaps Group the exciting potential of R&D 4.0 as a leading Softgel CDMO/CMO.
Discussion topics To gain an understanding of R&D 4.0 in the pharmaceutical industry, including its key principles and how it can help reduce time-to-market To learn about the benefits and challenges of utilizing advanced technologies such as 3D printing, Deep Learning, and Machine Learning in pharmaceutical development To explore real-world examples from Procaps on how these technologies have been used in pharmaceutical R&D, including in the development of complex drug delivery systems and the optimization of drug formulations specifically in Softgel advanced technologies Get a deeper insight on who Procaps Group is and how as a leading Softgel CDMO/CMO is incorporating these trends and technologies to achieve better time-to-market for its partners around the world

Digital transformation is a key area of development in pharma, but potential can be limited by regulatory roadblocks, a talent gap and integration complexities. Join our experts to gain insights into overcoming challenges and implementing the latest technologies: Becoming tech-led, not led by technology Managing change effectively Talent acquisition and onboarding Scaling across the organisation to avoid silos

Join our panel of experts to explore the tangible opportunities AI brings to pharma manufacturing: Improving batch manufacturing processes Efficient quality assurance and regulatory compliance Defining the role of chatbots and the potential for improving training and compliance standards in manufacturing set-ups Reviewing how AI can improve patient engagement

Sofgen Pharmaceuticals, part of Procaps Group, is an integrated Softgel CDMO that offers end-to-end solutions in Softgel technologies from development through delivery for prescription drugs, OTC products, and specialized nutraceuticals for pharmaceutical companies looking for differentiation, while simultaneously improving efficiency, and gaining access to specialized expertise, and unique technologies for their products.

Meet Unigel, the Smart Softgel. Proprietary technology by Procaps that allows multi-therapies in one single dose. Powerful combinations and formulations in Rx products customized to our customers´needs.

Get to know more about our integrated manufacturing capabilities and development expertise for companies seeking an ideal partner to help them grow and innovate.

Simplifying treatmentsthrough Innovationfor healthier patientsand a better planet:Unigel™ Case

As patients and consumers continue to seek for novel formats that deliver a completely new experience, CDMOs need to understand what consumers prefer in terms of oral dosage forms and try to satisfy those needs through innovative options. OTC and Nutritional Products are purchased by consumers based on their perceived value in addressing their health conditions or maintaining good health. We are landscape techniques widely accredited in the food industry and adapting them to the pharmaceutical landscape, achieving the chewability experience of our chewable soft gelatin capsules on a mechanical texture scale. At Procaps Group we take those needs into consideration and transform them into ideal technologies and Chewgels is a clear example of that. Our Chewgels technology consists of a chewable capsule that delivers an active ingredient without the need of water and with a delicious flavor making it a convenient, portable, on-the-go solution.

We are an integrated CDMO that offers end-to-end solutions, from developmentthroughout delivery, in innovative Softgel technologies for pharma andhealthcare companies interested in launching novel products within NorthAmerica and other Highly regulated markets.

In today’s rigid environment, being an essential partner in innovation in the pharmaceutical andnutraceutical industries means adapting and responding swiftly to the evolving landscape of medicaladvancements and market dynamics, it involves fostering a mindset that embraces change,collaboration, and agility.Procaps Group is your ideal flexible partner that fully understands the importance of staying ahead ofthe curve by actively seeking new opportunities, exploring novel technologies, anticipating emergingneeds and proximity to its customers.Throughout their different specialized facilities across North, Central & South America, ProcapsGroup’s iCDMO businesses Softigel®, Sofgen Pharmaceuticals®, Softcaps® Brazil, and Funtrition®, isable to offer extensive manufacturing capabilities, exclusive delivery systems and product developmentexpertise making them your ideal partner in softgel technologies.